-
2022-502548-12-00
5
2023-09-28
marginal zone lymphoma
-
2022-502959-54-00
5
2023-09-26
Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Ep
-
2022-501354-10-01
5
2023-06-21
axial spondyloarthritis
-
2022-501709-11-00
5
2023-06-06
Isocitrate deshydrogenase1 mutation-positive (IDH1m) acute myeloid leu
-
2022-500544-38-00
5
2023-06-05
Advanced Breast Cancer
-
2022-500609-42-00
4
2023-02-24
Anemia Due to Lower-Risk Myelodysplastic Syndromes
-
2023-509335-60-00
1
2023-02-23
Advanced solid tumors including (but not limited to), non-small cell l
-
2023-505277-32-00
5
2023-01-26
Diffuse Large B-Cell Lymphoma (DLBCL)
-
2023-506548-18-00
10
2022-11-10
Dermatitis atopic
-
2022-502425-18-00
5
2022-04-19
Adenocarcinoma of the prostate
-
2023-509248-86-00
10
2022-03-11
Moderately to Severely Active Ulcerative Colitis
-
2023-506145-38-00
3
2021-05-11
Treatment of participants with MF, MDS, ET, or MDS/MPN
-
2023-508922-83-00
10
2021-03-17
Advanced Non-Small Cell Lung Cancer
-
2024-511267-28-00
5
2021-02-17
B-cell malignancies
-
2022-501687-18-00
4
2020-10-28
Advanced malignancies and IAI diseases
-
2023-505261-84-00
5
2020-10-06
Primary high risk leiomyosarcoma or liposarcoma of retroperitoneal spa
-
2024-518223-29-00
4
2020-03-10
Advanced or metastatic untreated EGFR mutation positive NSCLC
-
2024-512972-36-00
9
2019-05-23
Indolent B-Cell Non-Hodgkin Lymphoma
-
2024-512683-53-00
6
2018-05-18
Non-muscle invasive bladder cancer
-
2025-522542-40-00
5
2026-06-19
Acute Ischemic Stroke
-
2025-521587-35-00
5
2026-06-03
Metastatic colorectal cancer
-
2025-524192-24-00
1
2026-05-29
advanced refractory solid tumors
-
2025-522007-18-00
5
2026-05-27
Relapsed or Refractory Multiple Myeloma
-
2023-503766-24-00
11
2026-05-26
Moderate to Severe Plaque Psoriasis